vs
Side-by-side financial comparison of BWX Technologies, Inc. (BWXT) and PERRIGO Co plc (PRGO). Click either name above to swap in a different company.
PERRIGO Co plc is the larger business by last-quarter revenue ($1.1B vs $885.8M, roughly 1.3× BWX Technologies, Inc.). BWX Technologies, Inc. runs the higher net margin — 10.5% vs -127.8%, a 138.3% gap on every dollar of revenue. On growth, BWX Technologies, Inc. posted the faster year-over-year revenue change (18.7% vs -2.5%). PERRIGO Co plc produced more free cash flow last quarter ($148.6M vs $56.8M). Over the past eight quarters, BWX Technologies, Inc.'s revenue compounded faster (21.1% CAGR vs 1.3%).
BWX Technologies, Inc. is a company headquartered in Lynchburg, Virginia that supplies nuclear components and fuel internationally.
Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters ...
BWXT vs PRGO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $885.8M | $1.1B |
| Net Profit | $93.0M | $-1.4B |
| Gross Margin | — | 32.6% |
| Operating Margin | 10.4% | -116.0% |
| Net Margin | 10.5% | -127.8% |
| Revenue YoY | 18.7% | -2.5% |
| Net Profit YoY | 30.9% | -3093.9% |
| EPS (diluted) | $1.02 | $-10.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $885.8M | $1.1B | ||
| Q3 25 | $866.3M | $1.0B | ||
| Q2 25 | $764.0M | $1.1B | ||
| Q1 25 | $682.3M | $1.0B | ||
| Q4 24 | $746.3M | $1.1B | ||
| Q3 24 | $672.0M | $1.1B | ||
| Q2 24 | $681.5M | $1.1B | ||
| Q1 24 | $604.0M | $1.1B |
| Q4 25 | $93.0M | $-1.4B | ||
| Q3 25 | $82.1M | $7.5M | ||
| Q2 25 | $78.4M | $-8.4M | ||
| Q1 25 | $75.5M | $-6.4M | ||
| Q4 24 | $71.0M | $-44.4M | ||
| Q3 24 | $69.5M | $-21.0M | ||
| Q2 24 | $73.0M | $-108.4M | ||
| Q1 24 | $68.5M | $2.0M |
| Q4 25 | — | 32.6% | ||
| Q3 25 | 21.8% | 36.1% | ||
| Q2 25 | 25.1% | 34.4% | ||
| Q1 25 | 24.2% | 37.6% | ||
| Q4 24 | — | 33.9% | ||
| Q3 24 | 24.4% | 37.2% | ||
| Q2 24 | 24.7% | 37.0% | ||
| Q1 24 | 24.6% | 33.1% |
| Q4 25 | 10.4% | -116.0% | ||
| Q3 25 | 13.1% | 7.0% | ||
| Q2 25 | 13.4% | 4.3% | ||
| Q1 25 | 14.2% | 4.5% | ||
| Q4 24 | 12.4% | 10.0% | ||
| Q3 24 | 14.4% | 7.4% | ||
| Q2 24 | 14.5% | -2.5% | ||
| Q1 24 | 15.4% | -5.1% |
| Q4 25 | 10.5% | -127.8% | ||
| Q3 25 | 9.5% | 0.7% | ||
| Q2 25 | 10.3% | -0.8% | ||
| Q1 25 | 11.1% | -0.6% | ||
| Q4 24 | 9.5% | -3.9% | ||
| Q3 24 | 10.3% | -1.9% | ||
| Q2 24 | 10.7% | -10.2% | ||
| Q1 24 | 11.3% | 0.2% |
| Q4 25 | $1.02 | $-10.23 | ||
| Q3 25 | $0.89 | $0.05 | ||
| Q2 25 | $0.85 | $-0.06 | ||
| Q1 25 | $0.82 | $-0.05 | ||
| Q4 24 | $0.77 | $-0.32 | ||
| Q3 24 | $0.76 | $-0.15 | ||
| Q2 24 | $0.79 | $-0.79 | ||
| Q1 24 | $0.75 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $499.8M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $2.9B |
| Total Assets | $4.3B | $8.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $499.8M | — | ||
| Q3 25 | $79.6M | $432.1M | ||
| Q2 25 | $37.0M | $454.2M | ||
| Q1 25 | $55.4M | $409.9M | ||
| Q4 24 | $74.1M | $558.8M | ||
| Q3 24 | $35.5M | $1.5B | ||
| Q2 24 | $48.3M | $542.8M | ||
| Q1 24 | $45.9M | $658.5M |
| Q4 25 | $1.2B | $2.9B | ||
| Q3 25 | $1.2B | $4.4B | ||
| Q2 25 | $1.2B | $4.5B | ||
| Q1 25 | $1.1B | $4.4B | ||
| Q4 24 | $1.1B | $4.3B | ||
| Q3 24 | $1.1B | $4.6B | ||
| Q2 24 | $998.5M | $4.5B | ||
| Q1 24 | $946.2M | $4.7B |
| Q4 25 | $4.3B | $8.5B | ||
| Q3 25 | $3.8B | $10.1B | ||
| Q2 25 | $3.7B | $10.1B | ||
| Q1 25 | $3.1B | $9.8B | ||
| Q4 24 | $2.9B | $9.6B | ||
| Q3 24 | $2.9B | $11.2B | ||
| Q2 24 | $2.8B | $10.4B | ||
| Q1 24 | $2.8B | $10.6B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $127.0M | $175.4M |
| Free Cash FlowOCF − Capex | $56.8M | $148.6M |
| FCF MarginFCF / Revenue | 6.4% | 13.4% |
| Capex IntensityCapex / Revenue | 7.9% | 2.4% |
| Cash ConversionOCF / Net Profit | 1.37× | — |
| TTM Free Cash FlowTrailing 4 quarters | $295.3M | $145.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $127.0M | $175.4M | ||
| Q3 25 | $143.2M | $51.7M | ||
| Q2 25 | $159.0M | $75.9M | ||
| Q1 25 | $50.6M | $-64.5M | ||
| Q4 24 | $276.9M | $312.6M | ||
| Q3 24 | $32.6M | $42.2M | ||
| Q2 24 | $65.9M | $9.5M | ||
| Q1 24 | $33.0M | $-1.4M |
| Q4 25 | $56.8M | $148.6M | ||
| Q3 25 | $94.9M | $29.8M | ||
| Q2 25 | $126.3M | $56.7M | ||
| Q1 25 | $17.3M | $-90.0M | ||
| Q4 24 | $224.4M | $274.9M | ||
| Q3 24 | $-7.7M | $15.1M | ||
| Q2 24 | $35.5M | $-18.9M | ||
| Q1 24 | $2.6M | $-26.5M |
| Q4 25 | 6.4% | 13.4% | ||
| Q3 25 | 11.0% | 2.9% | ||
| Q2 25 | 16.5% | 5.4% | ||
| Q1 25 | 2.5% | -8.6% | ||
| Q4 24 | 30.1% | 24.2% | ||
| Q3 24 | -1.1% | 1.4% | ||
| Q2 24 | 5.2% | -1.8% | ||
| Q1 24 | 0.4% | -2.4% |
| Q4 25 | 7.9% | 2.4% | ||
| Q3 25 | 5.6% | 2.1% | ||
| Q2 25 | 4.3% | 1.8% | ||
| Q1 25 | 4.9% | 2.4% | ||
| Q4 24 | 7.0% | 3.3% | ||
| Q3 24 | 6.0% | 2.5% | ||
| Q2 24 | 4.5% | 2.7% | ||
| Q1 24 | 5.0% | 2.3% |
| Q4 25 | 1.37× | — | ||
| Q3 25 | 1.74× | 6.89× | ||
| Q2 25 | 2.03× | — | ||
| Q1 25 | 0.67× | — | ||
| Q4 24 | 3.90× | — | ||
| Q3 24 | 0.47× | — | ||
| Q2 24 | 0.90× | — | ||
| Q1 24 | 0.48× | -0.70× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BWXT
| Nuclear Component Program | $436.4M | 49% |
| Nuclear Manufacturing | $134.8M | 15% |
| Cost Plus Fee | $116.1M | 13% |
| Uranium And Nuclear Services | $103.8M | 12% |
| Commercial Operations | $49.0M | 6% |
| Commercial Operations Segment | $33.7M | 4% |
| Transferred At Point In Time | $1.3M | 0% |
PRGO
| Consumer Self Care Americas | $697.0M | 63% |
| Digestive Health | $123.9M | 11% |
| Nutrition | $108.3M | 10% |
| Healthy Lifestyle | $94.8M | 9% |
| Pain And Sleep Aids | $87.1M | 8% |
